Kornimate/medical-research-clean huggingface dataset:
method validation and evaluation of non-radioactive methods to measure glomerular filtration rate

Conditions: Kidney Function Issue; Diagnosis; Chronic Kidney Diseases

Summary: this study is a single centre intervention study to compare two methods of determining the measured glomerular filtration rate (mgfr). subjects who receive radioactively labeled iothalamate (125i) and hippuran (131i) within the framework of routine clinical care, will be co-administered iohexol. the primary trial endpoint is the mgfr when administered 125i-iothalamate and 131i-hippuran versus iohexol. by determining the mgfr using both iohexol and iothalamate in the same patients, a direct comparison of the two methods can be made in terms of their accuracy and precision. this makes it possible to determine the potential use of the non-radioactive measurement method as an alternative to the radioactive method and thus lower the overall radioactive burden for patients and personnel.


Eligibility criteria:
inclusion criteria: * scheduled to undergo a kidney function measurement test as part of standard care. * written informed consent. exclusion criteria: * history of hypersensitivity to iodinated contrast media or one of the excipients in the formulation of iohexol (trometamol, sodium calcium edetate, hydrochloric acid). * subjects with (suspected or known) thyrotoxicosis. * pregnant women and women of child-bearing potential who are not using reliable contraception. * patients who are unlikely to comply to the trial's procedure (non-compliance).

Keywords: mgfr kidney function exogenous filtration marker measured glomerular filtration rate iohexol iothalamate
efficacy and safety study of nimodipine to prevent mild cognitive impairment after acute ischemic strokes

Conditions: Stroke; Mild Cognitive Impairment

Summary: the trial was designed to test the hypothesis that early treatment with nimodipine has a positive effect on cognition impairment after acute ischemic stroke.

656 patients diagnosed with acute cerebral ischemia disease (onset≤7d) based on icd-10 and ct/mri criteria, who have cognitive impairment meeting all of the inclusion criteria and none of the exclusion criteria, will be included and randomized into nimodipine treatment group and the controlled group.evaluations of cognitive function will be taken at baseline, 1 month, 3 months, and 6 months.

Eligibility criteria:
inclusion criteria: * 1. subjects between 30 and 80 years. * 2. icd-10 and ct/mri criteria for acute cerebral infarction. * 3. stroke within 7 days after onset. * 4.based on years of education correction.mmse\>17(illiteracy),mmse\>20(primary school),mmse\>24(others) * 5. moca≤26 at baseline. * 6.hachinski ischemic score ≥7 at baseline. * 7.expected good compliance to study. * 8.informed consent signed. exclusion criteria: * 1.diagnosis of schizophrenia, major anxiety syndrome, major depression. * 2.alzheimer disease, parkinson disease, huntington disease, and fronto-temporal dementia. * 3.dementia caused by (e.g., central nervous system trauma, tumor, infections, metabolic disorders, normal pressure hydrocephalus, lack of folic acid or vitamin b12, or thyroid hormone deficiency). * 4.contraindications to dihydropyridine derivatives. * 5.aphasia or other diseases that affect cognitive evaluation. * 6.serious arrhythmias, bradycardia (\ 120 bpm); myocardial infarction within the past 6 months; blood pressure \<90/60mmhg; severe renal or hepatic insufficiency; severe anemia, hb\<100g/l; severe gastrointestinal disorders; tumor. * 7.history of epilepsy, use of the antiepileptic drugs. * 8.ct/mri showed neurodegenerative changes or other lesions except cerebral ischemia.

Keywords: stroke mild cognitive impairment nimodipine
od vs. tid dosing with mesalazine granules in active ulcerative colitis

Conditions: Ulcerative Colitis

Summary: to proof the therapeutic equivalence of once daily (od) versus three times daily (tid) dosing of total 3.0 g mesalazine granules in patients with active ulcerative colitis


Eligibility criteria:
inclusion criteria (main): * active ulcerative colitis except proctitis, i.e. inflammation minimal 15cm ab ano, confirmed by endoscopy and histology * established or new diagnosis * disease activity at baseline: clinical activity index (cai) \>4 and endoscopic index (ei) \>= 4 exclusion criteria (main): * crohn's disease * toxic megacolon * present or past colorectal cancer * symptomatic gastrointestinal disease * serious secondary disease(s) * baseline stool positive for germs causing bowel disease * immunosuppressants within 3 months and/or corticosteroids within 1 month prior to baseline * current relapse occurred under maintenance treatment with \>2g/day mesalazine * serum creatinine \>= 1.2x upper limit of normal (uln) and creatinine clearance \< 60 ml/min per 1.73 m2 * serum transaminase (alt and/or ast), and/or alkaline phosphatase \>= 2x uln
risk of rupture of aneurysms of the thoracic ascending aorta (ata) from the dynamic imaging

Conditions: Aortic Aneurysm, Thoracic

Summary: aneurysms of the thoracic ascending aorta are a serious pathology which may threatens life by rupture or dissection. their incidence is estimated at 10.4 per 100,000 people. at present, the only parameter for assessing the risk of complication is the maximum diameter of the aneurysm. the only way to avoid a complication is a surgical replacement of the aneurysmal aorta by a prosthetic tube. this procedure is performed by sternotomy and with extracorporeal circulation and its death rate ranges between 3% and 5%. surgical repair is indicated when the diameter of the aneurysm exceeds 5.5 cm for degenerative atheromatous aneurysms or 5 cm in a patient with genetic disorder of connective tissue (marfan disease or ehlers-danlos syndrome). however, there are aneurysms with diameter greater than the surgical threshold which remain stable. conversely, complications have been described for aneurysms less than 4.5 cm in diameter. the criterion of diameter appears therefore as inadequate to assess the risk of complication of an aneurysm of the ascending aorta.multiple methods have been described in the literature. one of them relies on in vitro mechanical testing on healthy or aneurysmal tissue. another method is the vivo analysis from imaging (ct, mri or ultrasound). so far, no algorithm is robust enough for predicting the risk of complication better than the universally used criterion of diameter. the pathophysiology of these aneurysms has also been explored from histological studies. the investigators know that the microstructure of the aortic wall of an aneurysm is deteriorated with a degradation of elastin fibers and collagen that determine to a large extent its biomechanical behavior. histological analysis appears inseparable from biomechanical analysis.


Eligibility criteria:
inclusion criteria: * diameter of ata exceeds 5.5 cm * diameter of ata exceeds 5 cm in a patient with genetic disorder of connective tissue (marfan disease or ehlers-danlos syndrome) * diameter of ata exceeds 5 cm in a patient with aortic valvulopathy * written consent exclusion criteria: * contra-indication to mri * chronic insufficiency kidney

Keywords: aortic aneurysm thoracic ascending aorta ata dynamic imaging mechanical testing
gram-negative bacilli and mrsa screening in icu in china

Conditions: Infections, Bacterial

Summary: carbapenem-resistant gram-negative bacilli \[carbapenem-resistant acinetobacter baumannii (crab), carbapenem-resistant klebsiella pneumoniae (crkp), and carbapenem-resistant pseudomonas aeruginosa (crpsa) \] and methicillin-resistant staphylococcus aureus (mrsa) is prevalent around the world, and the isolation rate and resistance rate has increasing in china. the limited treatment and high mortality rate of these pathogens infections has resulted in difficulty in clinical anti-infection treatment, so it is urgent to illustrate the transmission mechanism, resistance mechanism and horizontal transfer mechanism of resistance genes in intensive care unit (icu). furthermore, this study was aimed to investigate the epidemiology and risk factors, outcomes and the rationality of the current therapy for these pathogens infections in china.

based on the previous study, investigators plan to screen for crkp, crab, crpsa and mrsa isolates from icu settings, medical workers and patients, and establish the crkp, crab, crpsa and mrsa genome and transcriptome database through next-generation sequencing. under the guide of british bioinformatics and hospital-acquired infection control experts, investigators will build the transmission mechanism model of crkp, crab, crpsa and mrsa combined with the clinical data to reveal the route and rule of transmission. and the study will also demonstrate that the resistance mechanism and horizontal transfer mechanism of resistance genes of carbapenems and other main antimicrobial agents. investigators will also set up alerting platform and new antibiotic susceptible system based on the genome and transcriptome. these results will provide scientific evidence to rational application of antimicrobial agents, reduction the prevalence of crkp, crab, crpsa and mrsa, improvement the prognosis of infections and development of new antimicrobial agents. finally, to find the prevalence, risk factors, outcome and the rationality of the current therapy for these pathogens infections in china.

Eligibility criteria:
inclusion criteria: * patients infected by crab isolated from throat swabs, rectal swabs, gastric tubes, tracheal intubations, tracheostomy tubes, and nasointestinal tubes * patients infected by crkp isolated from throat swabs, rectal swabs, gastric tubes, tracheal intubations, tracheostomy tubes, and nasointestinal tubes * patients infected by crpsa isolated from throat swabs, rectal swabs, gastric tubes, tracheal intubations, tracheostomy tubes, and nasointestinal tubes * patients infected by mrsa collected from throat swabs, rectal swabs, gastric tubes, tracheal intubations, tracheostomy tubes, and nasointestinal tubes exclusion criteria: * mixed infections of other pathogens * virus infections * other infections caused by other pathogens, such as fungus
association of inflammatory markers with preoperative anxiety and agitation

Conditions: Preoperative Anxiety; Emergence Agitation

Summary: this study was planned as a prospective, observational study. the study will include pediatric patients aged 3-12 who will undergo surgery. our hypothesis is that haemogram parameters, which are a simple, cheap and accessible method, and the inflammatory markers we obtain from them are associated with preoperative anxiety and emergence delirium

inclusion criteria for the study: pediatric patients aged 5-12 years, in the asa i-ii groups, who will undergo surgery in ophthalmology, urological surgery, ent surgery, pediatric surgery, orthopedic and plastic surgery. exclusion criteria for the study can be listed as follows: those with genetic diseases affecting brain development, those diagnosed with psychiatric and neurological diseases, patients with attention deficit, mental retardation, those with hematological and/or immune system disorders, patients who will undergo surgery in neurosurgery and cardiovascular surgery. during the preoperative visit, parents and children will be informed and their written and verbal consent will be obtained. patients will be taken to the preoperative waiting room and hemogram values and ratios (wbc, rbc, hematocrit, monocyte count, neutrophil count, lymphocyte count, platelet count, pdw, mpv, mlr, nlr, nmr, plr, pmr, pnr, pwr, sii) will be recorded from medical records. demographic data (including age, gender, bmi, asa score, fasting time, previous surgery, hospitalization status, the use of steroid), preoperative anxiety score (to be assessed with m-ypas turkish version), parental accompaniment, anxiety score of the parent (to be assessed with likert scale), preoperative medication application, medications used in anesthesia, airway device, surgery and anesthesia durations will be recorded. the paed score will be used for delirium agitation and all values will be recorded during the first 30 min. pain scores (flacc and vas) will be recorded in the case report form.

Eligibility criteria:
inclusion criteria: * pediatric patients aged 5-12 years * asa i-ii groups * pediatric patients who will undergo surgery in ophthalmology, urological surgery, ent surgery, pediatric surgery, orthopedic and plastic surgery. exclusion criteria: * those with genetic disorders affecting brain development * those diagnosed with psychiatric and neurological diseases * patients with attention deficit, mental retardation * patients with hematological and/or immune system disorders * patients who will undergo surgery in neurosurgery and cardiovascular surgery.

Keywords: children preoperative anxiety emergence agitation inflammation
pharmacokinetics of immediate-release vs. delayed-release omeprazole in gastroparesis

Conditions: Gastroparesis; Gastroesophageal Reflux Disease

Summary: the purpose of this study is to compare the blood drug levels of two prescribed medications, immediate-release omeprazole 40 mg powder and delayed-release omeprazole 40 mg capsule to determine which drug is better absorbed in patients with a slow stomach emptying (gastroparesis). delayed-release omeprazole has a protective coating to prevent the drug omeprazole from being neutralized by stomach acid. immediate-release omeprazole has sodium bicarbonate (antacid) which neutralizes the stomach acid, eliminating the need for a protective coating. immediate-release omeprazole suspension may have a more rapid pharmacokinetic profile and greater overall drug absorption in gastroparesis.

hypothesis: immediate-release omeprazole suspension may have a more rapid pharmacokinetic profile and greater overall drug absorption in gastroparesis. this will result in shorter time to maximal drug concentration, greater maximal concentration, and greater total area under the curve of the concentration vs. time plot. primary objective: to compare the pharmacokinetics of omeprazole between immediate-release suspension and delayed-release capsules in patients with heartburn associated with gastroparesis. study design: randomized, open-labeled, crossover treatment for 7 days with 10-14 days washout. pharmacokinetic studies will be performed after 7 days on study drug.

Eligibility criteria:
inclusion criteria: * symptoms of heartburn \>2 days per week off antireflux therapy, defined by "a burning feeling rising from the stomach or lower chest up towards the neck" * symptoms of gastroparesis \>1 month in duration, defined by nausea, vomiting, bloating, dyspepsia, early satiety, or effortless regurgitation. * prior abnormal 4-hour gastric emptying scan within the past 3 years exclusion criteria: * history of esophageal or gastric surgery * severe gastroparesis with any of the following: vomiting with dehydration requiring iv hydration, hospitalization, weight loss \>10 % pre-illness weight, requiring feeding jejunostomy tubes * presence of gastric electrical stimulator * symptoms of retching with vomiting more than 2 days per week * diagnosis of diabetes * disorders of small bowel motility (such as pseudo-obstruction or dumping syndrome) * disorders of small bowel absorption * diagnosis of gastric outlet, small bowel or colon mechanical obstruction * diagnosis of acid hypersecretory syndrome * disorders affecting proton pump inhibitor metabolism (such as liver failure) * known allergy or side effects to proton pump inhibitor * non-ambulatory patients: bed-ridden, nursing home resident, etc. * pregnancy

Keywords: gastroparesis gastroesophageal reflux disease heartburn
effects of a comprehensive weight management program on obese adolescents and children

Conditions: Pediatric Obesity; Insulin Resistance; Hyperinsulinemia

Summary: to compare anthropometric and metabolic effects of a comprehensive weight management program on obese adolescents and children in comparison to regular clinical weight management visits.

patients are randomized (2:1) to either the intensive or standard treatment (control). those who get randomized into the intensive group go to a family-based weight management program, including exercise, nutrition, behavior modification, and parenting classes. the intensive group is further randomized into a diet or non-dieting class to compare the outcomes of two different nutrition intervention methods. these classes meet twice per week (exercise twice per week and nutrition/behavior modification once per week)for first six months and then only twice per month during last six months. an exercise physiologist supervises the exercise component, which involves 45 minutes of aerobic activity (targeted at 65 to 80 percent of the subject's estimated maximum heart rate. a registered dietitian facilitates the nutrition and behavior component. a social worker facilitates parent classes when the children have a behavior modification topic in their class (parents only attend nutrition sessions). those who get randomized into the control group go to clinic visits every 6 months. intervention subjects go to clinic, as well, every 6 months to obtain the same measurements as the controls (weight, bmi, % fat, fasting insulin, fasting glucose, lipids, blood pressure).

Eligibility criteria:
inclusion criteria: * ages 8-16 years old * bmi \>95th percentile for age/gender based on cdc * both primary caregiver/parent and child must agree to participate in the nutrition classes exclusion criteria: * endocrinopathies, including hypothyroidism and diabetes * psychiatric disorders that will interfere with ability to complete follow-up and adherence to protocol * any behavioral or psychosocial issue that will interfere with subject's completion of program, including eating disorder. * any use of medication (steroids, for ex.) that contributes to excess adiposity. * any use of pharmacological intervention for weight management, including prescription medications, over-the-counter medications, or herbal supplements. * any concurrent membership in a weight management program. * inability or unwillingness of parent to accompany the child to nutrition classes. * pregnancy

Keywords: pediatric obesity overweight insulin resistance hyperinsulinemia weight management program family-based
assessment of treatment patterns of severe asthmatic patients across the gulf region - seveos study

Conditions: Severe Asthma

Summary: seveos is a cross-sectional, multi-center, non-interventional study aimed to describe the treatment patterns in 250 severe asthma patients across the gulf region. in addition, the study will determine the current level of asthma control and quality of life in these patients; describe the exacerbation patterns; and determine the current levels of blood eosinophils for the enrolled patients.

the primary objective of this study is to describe the treatments patterns of severe asthmatic patients across four gulf countries during the past year. secondary objectives 1. to determine the current level of asthma control in these patients. in addition, a comparison of uncontrolled asthma between those with a eosinophilic count ≥ 300 cell/μl and those with an elevated eosinophilic count less than that. 2. to determine the current and past year levels of blood eosinophils, and the percentage of patients with elevated eosinophilic level ≥ 150 cells/μl and ≥ 300 cells/μl 3. to describe the frequency of exacerbations during the past year. 4. to assess the current quality of life (qol) of these patients. 5. to determine the past year levels of serum ige. 6. exploratory objective: to determine the past year levels of other inflammatory biomarkers like periostin and fraction of exhaled nitric oxide (feno).

Eligibility criteria:
inclusion criteria: to be included in this study, patients (both male and female) must fulfill all of the following criteria: 1. age above 12 years. 2. body weight of ≥40 kg. 3. diagnosed by a physician with severe asthma, who requires regular treatment with medium or high dosage inhaled corticosteroids (ics) (patients aged 12-17 years) or high-dosage ics ( plus long-acting beta agonist (laba) for at least 1 year before enrolment. \[note that the value of the medium/high dosage is dependent on the type of ics exclusion criteria: patients who meet any of the following criteria are ineligible to participate in the study: 1. patient refuses to consent. 2. another clinically important pulmonary disease is considered to be the primary diagnosis, other than severe asthma (i.e.: copd, major bronchiectasis, active tuberculosis, and other conditions considered by the principal investigator). 3. mentally disabled patient or inability to understand the study questions. 4. unable to read/write.
comparison of shoulder stretches

Conditions: Shoulder Impingement; Shoulder Pain; Adhesive Capsulitis; Rotator Cuff Tears; Posterior Capsule Tear; Glenohumeral Subluxation; Glenohumeral Dysplasia; Acromioclavicular; Sprain (Strain); Internal Rotation Contracture-shoulder; External Rotation Contracture-Shoulder; Flexion Contracture; Extension Contracture-Shoulder

Summary: various stretches are used to lengthen the posterior shoulder capsule. no study has reported the comparison of the pragmatic posterior capsular stretch and cross body stertch

background: posterior capsular tightness (pct) is frequently seen in shoulders in athletic population and shoulder disoders. pct leads to variation in scapular and humeral kinematics. two techniques considered in our study for regaining normal range of motion at shoulder joint and improving pct, one is the pragmatic posterior capsular stretch (ppcs) \& the other one is cross body stretch (cbs) objective: the aim of our study id to compare the short term/intermediate term effect of ppcs and cbs on range of motion on shoulder joint in healthy individuals. and to evaluate the feedback of subjects regarding both the interventions. methodology: sixty a symtomatic shoulder of 30 subjects (15 males, 15 females) were recruited for this restricted randomised control trials. a simple random sampling technique was used. subjects were screen through a functional movement screening tool of shoulder mobility. the change in hand behind neck and hand behind back will be measured through measuring tape. shoulder rom and functional movements for both the stretches will be campared. particpants will be follwed for 4 weeks for the change in their shoulder range of motion.

Eligibility criteria:
inclusion criteria: * age groups of males and females including 20-35 years * subjects who fall in grade 1 and 2 of functional movement screening of shoulder during the screening process. exclusion criteria: * individual with shoulder pain, fracture or dislocation less than 1 year * individuals with any known shoulder pathology * subjects receiving current physiotherapy treatment * subjects having enough range of motion( can reach t2 hand behind neck)
flipped autograft for treating surgical wound dehiscence

Conditions: Wound Dehiscence

Summary: this case report describes a novel technique for management of peri-implant wound dehiscence that involves using auto graft from the same surgical site to seal the dehiscence defect.


Eligibility criteria:
inclusion criteria: 1. adult patients in a healthy systemic condition. 2. both genders 3. patients should have single missing tooth. 4. seibert class i ridge defect. 5. patients should approve to deliver a signature to a written consent after study nature explanation. exclusion criteria: * 1- patients with any smoking habits. 2- pregnant females, decisional impaired individuals, prisoners and handicapped patients. 3- patients having poor oral hygiene or not wanting to carry out oral hygiene measures. 4- patients with infections either periodontally or periapically.